Reduction of infarct size by the early use of intravenous timolol in acute myocardial infarction. International Collaborative Study Group.
One hundred forty-four patients admitted to the hospital within 4 hours after the onset of symptoms of suspected acute myocardial infarction (AMI) were randomly assigned to either intravenous timolol treatment or to matching placebo. Infarct evolution was assessed by continuous vectorcardiography and CK release. Timolol reduced myocardial ischemia and infarct size as measured by an accelerated reduction in ST-vector magnitude, a significant reduction in maximal cumulative CK release (29.5%) and significantly smaller changes in QRS-vector parameters (20 to 25%). Furthermore, the predicted CK release and maximal QRS-vector change for a given initial ST-vector magnitude was significantly reduced by timolol. The drug regimen also caused a significant reduction in pain and the need for analgesic medication.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004796:Clinical Enzyme Tests; D002986:Clinical Trials as Topic; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy*; D010919:Placebos; D013997:Time Factors; D013999:Timolol / Q000627:therapeutic use*; D014672:Vectorcardiography
D010919:Placebos; D013999:Timolol; D003402:Creatine Kinase